EP1007048A4 - Identification of agents for use in the treatment of alzheimer's disease - Google Patents

Identification of agents for use in the treatment of alzheimer's disease

Info

Publication number
EP1007048A4
EP1007048A4 EP98911551A EP98911551A EP1007048A4 EP 1007048 A4 EP1007048 A4 EP 1007048A4 EP 98911551 A EP98911551 A EP 98911551A EP 98911551 A EP98911551 A EP 98911551A EP 1007048 A4 EP1007048 A4 EP 1007048A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
agents
identification
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98911551A
Other languages
German (de)
French (fr)
Other versions
EP1007048A1 (en
Inventor
Ashley I Bush
Xudong Huang
Craig S Atwood
Rudolph E Tanzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1007048A1 publication Critical patent/EP1007048A1/en
Publication of EP1007048A4 publication Critical patent/EP1007048A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
EP98911551A 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease Withdrawn EP1007048A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81612297A 1997-03-11 1997-03-11
US816122 1997-03-11
PCT/US1998/004683 WO1998040071A1 (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EP1007048A1 EP1007048A1 (en) 2000-06-14
EP1007048A4 true EP1007048A4 (en) 2004-09-22

Family

ID=25219748

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98911551A Withdrawn EP1007048A4 (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Country Status (5)

Country Link
EP (1) EP1007048A4 (en)
JP (1) JP2001514661A (en)
AU (1) AU748768B2 (en)
CA (1) CA2284170C (en)
WO (1) WO1998040071A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
AU741782B2 (en) 1997-08-21 2001-12-06 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of Alzheimer's disease
US6316269B1 (en) 1997-10-06 2001-11-13 The General Hospital Corporation Methods for screening drugs to predict tardive dyskinesia
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) * 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
CN1324234A (en) 1998-09-25 2001-11-28 格利科克斯有限公司 Fructosamine oxidase: antagonists and inhibitors
AU1792200A (en) 1999-01-07 2000-07-24 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment
DE19909357A1 (en) * 1999-03-03 2000-09-07 Gerd Multhaup Copper agonist that binds to the APP copper binding site and / or has an inhibitory effect on the release of the amyloid-Aß peptide
ATE445639T1 (en) * 1999-08-04 2009-10-15 Univ Southern California GLOBULAR STRUCTURE OF AMYLOID BETA PROTEIN AND THEIR USES
US20030138374A1 (en) * 2000-03-22 2003-07-24 Yukitsuda Kudo Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
AU2002351880B2 (en) * 2001-12-27 2007-08-30 Neuroscientific Biopharmaceuticals Pty Ltd Screening methods and the use of agents identified using the same
WO2003077901A1 (en) 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
JP2006503014A (en) 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド Dosage forms and related treatments
US20070185072A1 (en) * 2003-03-21 2007-08-09 Christophe Boldron Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
CA2536393A1 (en) * 2003-09-09 2005-06-16 Gilead Sciences, Inc. Use of liposomes which are small unilamellar vesicles for the removal of an entity from a biological sample
AU2004298393A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
ES2449066T3 (en) 2004-07-19 2014-03-18 Philera New Zealand Limited Synthesis of triethylenetetramines
CA2570324C (en) 2004-08-03 2014-07-22 Transtech Pharma, Inc. Rage fusion proteins and methods of use
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
CN101842382A (en) 2007-06-14 2010-09-22 卡拉狄加制药公司 PAGE fusion proteins
US8815936B2 (en) 2008-03-03 2014-08-26 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2018236221A2 (en) * 2017-06-03 2018-12-27 Can Holding B.V. Neurodegenerative peptide deposit dissolution
KR102048846B1 (en) * 2017-11-20 2019-11-27 한국생명공학연구원 Medicine for treating vascular disease and method for screening the same
CN114555071A (en) * 2019-07-25 2022-05-27 学校法人东京理科大学 Agents for treating, preventing or ameliorating diseases or symptoms of the mental/neurological system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681844A1 (en) * 1993-11-30 1995-11-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substance for detecting amyloid deposition
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
EP0613560B2 (en) * 1991-11-12 2006-06-21 Prana Biotechnology Ltd A method for assaying and treating alzheimer's disease
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ES2175083T3 (en) * 1995-03-14 2002-11-16 Praecis Pharm Inc AMULOID AGGREGATION MODULATORS.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681844A1 (en) * 1993-11-30 1995-11-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Substance for detecting amyloid deposition
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BACON ET AL: "Rheumatoid Diesease, Amyloidosis and its Treatment with Penicillamine", EUROPEAN JOURNAL OF RHEUMATOLOGY AND INFLAMMATION, CAMERON PUBLISHERS, CASTLETOWN, GB, vol. 3, no. 2, 1979, pages 70 - 74, XP002117959, ISSN: 0104-1610 *
See also references of WO9840071A1 *

Also Published As

Publication number Publication date
EP1007048A1 (en) 2000-06-14
JP2001514661A (en) 2001-09-11
CA2284170A1 (en) 1998-09-17
WO1998040071A1 (en) 1998-09-17
CA2284170C (en) 2008-12-02
AU6548498A (en) 1998-09-29
AU748768B2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
EP1043991A4 (en) Treatment for alzheimer's disease
HUP0103838A3 (en) Alzheimer's disease secretase
PL348226A1 (en) Compounds for the antemortem diagnosis of alzheimer's disease and in vivo
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
EP0735870A4 (en) Use of pla 2? inhibitors as treatment for alzheimer's disease
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
EP1015013A4 (en) TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
ZA989365B (en) Preparation for treating alzheimer's disease
IL127146A0 (en) Transdermal propentofylline compositions for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
GB0011408D0 (en) Therapeutic combination for treating Alzheimer's Disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
AU5495398A (en) Idebenone containing combination agent for treating alzheimer's disease
AU2002301084A1 (en) Identification of agents for use in the treatment of alzheimer's disease
HUP0103149A3 (en) Pharmaceutical composition for treatment of alzheimer's disease
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes
HU9600725D0 (en) Transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine for the treatment of alzheimer's disease
ZA98118B (en) Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 01N 59/08 B

Ipc: 7A 01N 43/60 B

Ipc: 7A 01N 43/40 B

Ipc: 7A 01N 43/38 B

Ipc: 7A 01N 43/32 B

Ipc: 7A 01N 43/00 B

Ipc: 7A 01N 37/18 B

Ipc: 7A 01N 37/12 B

Ipc: 7A 61K 49/00 B

Ipc: 7A 61K 38/17 B

Ipc: 7A 61K 31/545 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040811

17Q First examination report despatched

Effective date: 20050421

17Q First examination report despatched

Effective date: 20050421

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20081212BHEP

Ipc: A61K 38/17 20060101ALI20081212BHEP

Ipc: A61K 31/545 20060101AFI20081212BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090721